Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer
24 novembre 2020 aggiornato da: Eli Lilly and Company
A Phase II Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Carcinoma
The purpose is to assess the efficacy and toxicity of the study agent, enzastaurin, in participants with recurrent or persistent ovarian cancer.
Panoramica dello studio
Stato
Completato
Condizioni
Intervento / Trattamento
Tipo di studio
Interventistico
Iscrizione (Effettivo)
28
Fase
- Fase 2
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19103
- Gynecologic Oncology Group 215-854-0770
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
18 anni e precedenti (Adulto, Adulto più anziano)
Accetta volontari sani
No
Sessi ammissibili allo studio
Femmina
Descrizione
Inclusion Criteria:
- Participants must have recurrent or persistent epithelial ovarian or primary peritoneal carcinoma.
- All participants must have measurable disease.
- Participants must have at least one "target lesion" to be used to assess response on this protocol.
- Participants must not be eligible for a higher priority GOG protocol, if one exists.
- Participants who have received one prior regimen must have a GOG Performance Status of 0, 1, or 2. Participants who have received two prior regimens must have a GOG Performance Status of 0 or 1.
- Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration. Continuation of hormone replacement therapy is permitted.
- Any other prior therapy directed at the malignant tumor, including immunologic agents, must be discontinued at least four weeks prior to registration.
- Participants must have had one prior platinum-based chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound.
- Participants must NOT have received any non-cytotoxic therapy for management of recurrent or persistent disease.
- Participants of child-bearing potential must have a negative serum pregnancy test prior to study entry and be practicing an effective form of contraception (for example, intrauterine device [IUD], birth control pills, or barrier device) during and for 3 months after discontinuation of study treatment.
Exclusion Criteria:
- Participants with previous enzastaurin treatment.
- Participants who have received radiation to more than 25% of marrow-bearing areas
- Participants with other invasive malignancies, with the exception of non-melanoma skin cancer, who had (or have) any evidence of other cancer present within the last 5 years or whose previous cancer treatment contraindicates this protocol therapy.
- Participants who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
- Participants who are unable to discontinue use of carbamazepine, phenobarbital, and phenytoin (refer to Concomitant Medications for a discussion of enzyme inducing anti-epileptic drugs [EIAEDs]).
- Participants who are receiving concurrent administration of any other systemic anticancer therapy except for a biphosphonate if patient has bony metastases.
- Participants who have received prior therapy with non-cytotoxic agents (i.e. bevacizumab).
- Participants with serious concomitant systemic disorders (for example, active infection or abnormal electrocardiogram (ECG) indicative of cardiac disease) that, in the opinion of the investigator, would compromise the safety of the patient and his/her ability to complete the study.
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: UN
|
1125 mg loading dose then 500 mg, oral, daily, until progressive disease
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression-free Survival for at Least 6 Months (PFS-6)
Lasso di tempo: Baseline through 6 months
|
Data presented are the percentage of participants without progressive disease (PD) or death from any cause 6 months after registration.
PD was a 25% increase in the sum of products of all measurable lesions (or 2 largest lesions if too numerous) over the smallest sum observed (over baseline if no decrease) or clear worsening of any evaluable disease, or appearance of any new lesion/site, or failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).
|
Baseline through 6 months
|
|
Number of Participants With Adverse Events and Severe Adverse Events
Lasso di tempo: Baseline through end of study (Up to 45 months)
|
Data presented are the number of participants who experienced 1 or more adverse events (AEs) (all causalities and drug-related) and serious AEs (SAEs).
A summary of SAEs and other non-serious AEs, regardless of causality is located in the Reported Adverse Events section of this record.
|
Baseline through end of study (Up to 45 months)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Duration of Progression-Free Survival
Lasso di tempo: Baseline to disease progression (Up to 38 months)
|
PFS is defined as the rate of PFS from the date of diagnosis to the first date of objectively determined progressive disease (based on radiological assessment) or death from any cause.
It is assumed that PFS follows an exponential distribution.
|
Baseline to disease progression (Up to 38 months)
|
|
Prognostic Factors: Platinum Sensitivity
Lasso di tempo: Baseline
|
Participants who had disease progression within 6 months of ending their last regimen of platinum therapy were considered platinum resistant.
Participants who had disease progression between 6 and 12 months of ending their last platinum regimen were considered platinum sensitive.
Participants who had disease progression beyond 12 months of ending their last platinum regimen were also considered platinum sensitive.
|
Baseline
|
|
Prognostic Factors: Performance Status
Lasso di tempo: Baseline
|
Performance Status 0 = Fully active, able to carry on all pre-disease performance without restriction Performance Status 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of light or sedentary nature, e.g., light housework, office work.
|
Baseline
|
|
Overall Survival
Lasso di tempo: Baseline through end of study (Up to 45 months)
|
Overall survival (OS) time is defined as the time from the date of diagnosis to the date of death from any cause.
For participants who are still alive at the time of analysis, survival time will be censored at the last contact date.
|
Baseline through end of study (Up to 45 months)
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Collaboratori
Investigatori
- Direttore dello studio: Lydia Usha, Gynecologic Oncology Group
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio
1 gennaio 2007
Completamento primario (Effettivo)
1 maggio 2008
Completamento dello studio (Effettivo)
1 dicembre 2014
Date di iscrizione allo studio
Primo inviato
8 gennaio 2007
Primo inviato che soddisfa i criteri di controllo qualità
8 gennaio 2007
Primo Inserito (Stima)
11 gennaio 2007
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
19 dicembre 2020
Ultimo aggiornamento inviato che soddisfa i criteri QC
24 novembre 2020
Ultimo verificato
1 novembre 2020
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 10738
- H6Q-MC-S025 (Altro identificatore: Eli Lilly and Company)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .